Algae-derived polymers and bioactive compounds occupy a significant but frequently overlooked position in the pharmaceutical and medical device industries. Alginates derived from brown seaweed are widely used as wound dressing matrices, tablet binders and controlled-release excipients. Carrageenans from red algae serve as gel-forming excipients in oral drug formulations. Fucoidan, agar and certain pigment fractions are under active investigation as pharmacological candidates. When these materials are placed on the market for pharmaceutical or medical device applications, they bypass food law, cosmetics law and the novel food framework entirely — entering a different regulatory world with different competent authorities, substantially different data requirements and mandatory Good Manufacturing Practice (GMP) standards.

This chapter provides orientation at the boundary between the algae sector and pharmaceutical/medical device regulation. It is not a substitute for specialist regulatory affairs advice, which is essential for any product development in this space.

The single most practically important question in this area is the classification boundary between a food supplement and a medicinal product, and between a cosmetic and a medical device. The classification determines not only which regulatory framework applies but also which authority has jurisdiction, what data are required, and what claims may lawfully be made.

Under Directive 2001/83/EC on medicinal products for human use Eurlex, a substance is classified as a medicine either because of its presentation (it is presented as having properties for treating or preventing disease in humans) or because of its function (it is capable of restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action). Either criterion alone is sufficient — the “by function” definition is particularly important and has been confirmed by the CJEU in multiple rulings.

This means that:

• An algal extract sold as a food supplement with claims limited to normal physiological function (e.g. “supports immune health”) falls under food supplement law (Directive 2002/46/EC EURlex and national rules — see Food Supplements).
• The same extract, marketed with claims about treating, curing or preventing a specific disease, or with a pharmacological dose and a demonstration of pharmacological activity, is a medicinal product by presentation or by function, even if the extract itself is identical.
• A product that straddles this line will be classified as a medicinal product under Article 2(2) of Directive 2001/83/EC, which provides that in case of doubt, medicinal products law prevails.

National competent authorities (NCAs) — typically national medicines agencies — make these borderline determinations on a case-by-case basis. There is variation between member states, and a product classified as a food supplement in one member state may be classified as a medicine in another. The European Medicines Agency (EMA) provides guidance but does not itself classify borderline products; classification decisions rest with NCAs.

The boundary between a cosmetic and a medical device arises when an algae-based product is applied to the body but acts on a physiological function beyond the surface. Wound dressings, for example, are not cosmetics — they are medical devices. An alginate-based dressing that creates a moist wound environment, promotes autolytic debridement or controls exudate is functioning as a device. The mode of action (physical vs. pharmacological) determines classification: if the primary intended action is achieved by pharmacological, immunological or metabolic means, the product is a medicine, not a device.

Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices EURlex aims to ensure the smooth functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients and users, and taking into account the small- and medium-sized enterprises that are active in this sector. This regulation superseeded Council Directives 90/385/EEC and 93/42/EEC and amended Directive 2001/83/EC on the Community code relating to medicinal products for human use EURlex, Regulation (EC) No 178/2002 on general principles and requirements of food law (excluding medical devices from its scope) EURlex and Regulation (EC) No 1223/2009 on cosmetic products (excluding medical devices from its scope) EURlex.

Relevance to algae: The MDR is the primary EU legal framework for medical devices. It applies directly to algae-derived materials when they are:

• Wound dressings and wound care products — alginate fibre dressings (e.g. calcium alginate dressings used for exudating wounds) and hydrogel wound dressings containing algal polysaccharides are Class IIa or Class IIb medical devices under Annex VIII classification rules, depending on duration of use and wound contact.
• Drug delivery components — alginate microspheres, beads or capsules used to encapsulate APIs for controlled release are components of combination products or drug delivery systems; their classification depends on whether the primary mode of action is that of the device or the drug.
• Haemostatic products — alginate-based haemostats (for wound bleeding control) are Class III devices in some configurations.
• Dental materials — alginate impression materials used in dentistry are Class I or Class IIa devices.

Key requirements under MDR relevant to algae-derived devices:

• CE marking: All medical devices placed on the EU market must bear the CE mark, indicating conformity with the MDR's essential safety and performance requirements (Annex I).
• Classification: Devices are classified into Class I, IIa, IIb or III based on risk, using the classification rules in Annex VIII. Higher-class devices require involvement of a Notified Body.
• Technical documentation (Annex II and III): Comprehensive technical file including device description, design and manufacturing information, risk management, clinical data (or justification for equivalence), and post-market surveillance plan.
• Unique Device Identification (UDI): All devices must be registered in the EUDAMED database and carry a UDI code.
• GMP equivalent (Annex IX, Chapter I): Device manufacturers must implement a quality management system, in practice aligned to ISO 13485 (Quality Management Systems for Medical Devices).
• Clinical evidence: For Class IIa and above, sufficient clinical evidence of safety and performance is required. This may be based on clinical investigations or demonstration of equivalence to an existing device.

For alginate-derived wound dressings in particular, there is a well-established body of clinical evidence and many marketed products, which facilitates the equivalence route for new entrants. The regulatory pathway is demanding but not unprecedented.

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use EURlex.

Relevance to algae: This Directive is the principal EU legal framework for medicines. It is relevant to algae in the following contexts:

Several algae-derived compounds are established or candidate APIs:

• Pharmaceutical-grade omega-3 fatty acids (EPA, DHA) derived from microalgae (notably Schizochytrium sp. and Nannochloropsis) are used at prescription doses for the treatment of severe hypertriglyceridaemia and for cardiovascular risk reduction. Products such as icosapent ethyl (EPA ethyl ester) and omega-3-acid ethyl esters are authorised medicinal products in the EU. These products follow the standard medicinal product authorisation procedure (either centralised via EMA or national), with full clinical dossiers demonstrating efficacy and safety.
• Fucoidan (sulfated polysaccharide from brown seaweed) is under investigation for anticoagulant, antiviral and immunomodulatory effects. No fucoidan-based product has completed EU marketing authorisation as a medicine, but clinical investigations are ongoing.
• Phycocyanin and other cyanobacterial pigments are being investigated as candidates for photodynamic therapy.

Algae-derived compounds are used as pharmaceutical excipients — inactive ingredients that confer specific properties to the dosage form. Common examples:

• Agar (from red algae) — used as a gelling agent in microbiological culture media and historically in tablet manufacture, though now mostly replaced.
• Carrageenan — used as a suspending agent and binder in oral liquid and solid dosage forms.
• Alginate (sodium, potassium, calcium) — used as a disintegrant, binder and controlled-release matrix in oral tablets; also used as a viscosity-modifying agent in liquid formulations and as the basis for gastro-resistant coatings.

Pharmaceutical excipients do not require independent marketing authorisation — they are evaluated as part of the medicinal product's marketing authorisation dossier. However, manufacturers of pharmaceutical-grade excipients are expected to comply with the ICH Q7 guideline on GMP for APIs and with the relevant monographs in the European Pharmacopoeia (Ph. Eur.), which includes dedicated monographs for sodium alginate, carrageenan, agar and related substances.

• Centralised procedure (mandatory for biotechnology products, optional for others): application to EMA; authorisation valid across the EU.
• National procedure: application to a national competent authority; authorisation valid in one member state. Mutual recognition and decentralised procedures allow extension to other member states.
• Traditional herbal medicinal products: simplified procedure under Directive 2004/24/EC; not generally applicable to algae-derived products (which lack the required 30-year traditional use data including 15 years in the EU).
• Well-established use (Article 10a): available where a substance has been in well-established medicinal use in the EU for at least 10 years. Relevant for established omega-3 preparations.

All medicinal products and their APIs must be manufactured in accordance with the EU GMP guidelines, published by the European Commission under Directive 2001/83/EC. The main volumes relevant to algae-derived pharmaceutical materials are:

• Volume 4, Part I: GMP for medicinal products for human use — covers manufacturing authorisation, personnel, premises, equipment, documentation, production, quality control and outsourced activities.
• Volume 4, Part II: GMP for active substances used as starting materials — the pharmaceutical equivalent of a production quality system, applicable to facilities producing algae-derived APIs and excipients.

GMP compliance is audited by national competent authorities and is a pre-condition for inclusion of a manufacturing site in a marketing authorisation dossier. For algae producers supplying pharmaceutical-grade material, GMP certification is effectively a market access requirement, irrespective of whether the algae itself requires any form of authorisation.

The European Pharmacopoeia establishes quality standards (identity, purity, assay) for pharmaceutical-grade algal materials. Compliance with Ph. Eur. monographs is expected by regulatory authorities and buyers in the pharmaceutical supply chain.

Following years of negotiations, the final texts of the new EU Pharma Package (Directive and Regulation) were officially published in early 2026. HSFKramer. This package will fully replace and repeal Directive 2001/83/EC and Regulation (EC) No 726/2004 once it takes full effect (expected around 2028).

• Classify before you claim: the decision to market an algal product as a food supplement, a cosmetic or a pharmaceutical must be made before any claims are finalised; the claim determines the classification, and the classification determines the entire regulatory pathway and cost structure.
• Do not underestimate the borderline product risk: member state authorities actively enforce the food supplement / medicine boundary. An algal extract sold as a supplement that is found to exert pharmacological effects at marketed doses can be reclassified as an unauthorised medicine and removed from the market, with potential criminal liability.
• GMP compliance is a pre-competitive requirement: any producer intending to supply algal biomass or extracts into the pharmaceutical supply chain must implement GMP-equivalent quality systems well before attempting to enter that supply chain. Buyers will audit GMP as a condition of purchase.
• Consult the European Pharmacopoeia: for established algal materials (alginates, carrageenan, agar), the Ph. Eur. monograph defines the quality specification. Producers supplying pharmaceutical customers should characterise their material against the relevant monograph and document any deviations.
• Alginate wound dressings are an accessible entry point: of all pharmaceutical/device applications, CE-marked alginate wound dressings represent the most established pathway for algae producers. The regulatory requirements are demanding but well-documented, the clinical evidence base is large, and the market is established. This is the most realistic near-term application area in this regulatory space.

See also: Food Supplements | Novel Food | Cosmetics | Production, Processing and Hygiene | Purpose, Scope and Sources

Last reviewed: September 2026.